Figures

Fig. 1




Fig. 2




Fig. 3



Cumulative disease scores
(Mean + SEM)
80
60
40
20
0
**
Vehicle
Fingolimod

Fig. 4



Clinical Score
(Mean + SEM)
Vehicle
Fingolimod 0.03 mg/kg, q.d.
COMPOUND 100 mg/kg, b.i.d.
Combination
(n=10/group)
Treatment period
Days post immunization

Fig. 5



Maximal Clinical Score
(Mean + SEM)
4
3
2
1
0
*
ns
**
Vehicle
Fingolimod
COMPOUND
Combination

Fig. 6



Neurofilament light chain [pg/ml]
(Mean + SEM)
20000
15000
10000
5000
0
**
ns
*
**
IFA/PBS
Vehicle
Fingolimod
COMPOUND
Combination

Fig. 7



Lymphocytes (x10^3 cells/µl)
5
4
3
2
1
0
**
Vehicle
Fingolimod
COMPOUND
Combination

Fig. 8



CXCL12 (ng/mL)
8
7
6
5
4
3
2
1
0
****
****
****
****
Vehicle
Fingolimod
COMPOUND
Combination

Fig.9



****
*
**
100
50
0
% of myelin staining
(Mean + SEM)
Control
CPZ
COMPOUND prev-CPZ
COMPOUND ther-CPZ

Fig. 10



****
*
**
2000
1500
1000
500
0
Mature oligodendrocytes / mm2
(Mean + SEM)
Control
CPZ
COMPOUND prev-CPZ
COMPOUND ther-CPZ

Fig. 11



****
*
100
80
60
40
20
0
% of myelin staining
(Mean + SEM)
Control
CPZ
COMPOUND-CPZ
Fingolimod-CPZ

Fig. 12



60
40
20
0
Cumulative disease scores
(Mean + SEM)
*
*
Vehicle
10
100
150
COMPOUND
(mg/kg, b.i.d., p.o.)

Fig. 13



CXCL12 (ng/mL)
6
5
4
3
2
1
0
****
****
Vehicle
10
100
150
COMPOUND
(mg/kg, b.i.d., po)

Fig. 14




Max. fold change from baseline
2.5
2.0
1.5
1.0
0
50
100
150
200
Dose (mg)
Dose (mg)
1
3
10
30
100
200
Placebo

Fig. 15


Relative maximum change in CXCL12 (%)
100
75
50
25
0
0
1000
2000
3000
AUCτ COMPOUND (ng*h/mL)
Dose
1 mg
3 mg
10 mg
30 mg
100 mg